**Catalogue of Requirements**

**Neuro-oncology Centres**

Module in the Oncology Centre

**Prepared by the Certification Committee Neuro-oncological Tumours of the German Cancer Society**

**Chairs of the Certification Committee:** Prof. Dr. U. Schlegel, Prof. Dr. W. Stummer

**Members (in alphabetical order):**

ACO – Working Group for Surgical Oncology

ADT – Association of German Tumour Centres

OPH – Working Group for Psycho Oncology

PSO – Working Group Psycho-Oncology

AIO – Working Group for Internal Oncology

AGORS – Working Group for Oncological Rehabilitation and Social Medicine

APM – Working Group for Palliative Medicine

ARO – Working Group for Radio-Oncology

ASO – Working Group for Social Work in Oncology

AGSMO – Working Group for Supportive Measures in Oncology

BNHO – Association of Practice-based Haematologists and Oncologists in Germany

BDP – Association of German Pathologists

BVDST – German Professional Association of Radiation Therapists

CAO – Surgical Working Group for Oncology

DGCh – German Society of Surgery

DGHO – German Society of Haematology and Oncology

DeGIR – German Society of Interventional Radiology and Minimal-invasive Therapy

DGNC – German Society of Neurosurgery

DGN – German Society of Neurology

DGNN – German Society of Neuropathology and Neuroanatomy

GNP – German Society of Neuropsychology

DGNR – German Society of Neuroradiology

DGN – German Society of Nuclear Medicine

DGP – German Society of Palliative Medicine

DGP – German Society of Pathology

DEGRO – German Society of Radio-Oncology

DHH – German Brain Tumour Association

DRG – German X-Ray Society

DVE – German Association of Occupational Therapists

DVSG – German Association of Social Work in Health Care

Auditors

KOK – Conference on Oncological and Paediatric Nursing Staff

NOA – Neuro-oncology Working Group

Permanent guests:

* OncoSuisse

**Comments on the Catalouge of Requirements**

The Catalouge of Requirement and its appendices are binding for all centres.

|  |  |
| --- | --- |
| Audit year: | **2025** |
| Version: | **H1** |
| Date: | **16.08.2024** |

The changes marked in green in this Catalouge of Requirement (CoR) were decided in 2024 and are valid for all audits carried out from 01.01.2025.

Incorporated:

* Brief interdisciplinary DKG guidelines
* Neuro-oncological guidelines of the AWMF

The technical and medical requirements for organ-specific diagnostics and the treatment of neuro-oncological tumours within the Oncology Centres are laid down in this module.

When the tumour entity described in the available module is part of the Oncology Centre, then the technical and medical requirements specified here are the basis for the certification of the Oncology Centre.

The Catalogue of Requirements is based on the TNM classification of malignant tumours, 8th edition 2017, the ICD classification ICD-O-3 2021 (DIMDI) and the OPS classification OPS 2023 (DIMDI).

**Information on the Neuro-oncology Centre (MNOC)**

|  |  |
| --- | --- |
| Centre  |  |
| Director Centre |  |
| Coordinator of the Centre |  |

|  |  |
| --- | --- |
| Clinical site 1 (hospital/place) |  |
|  |  |
| Clinical site 2 (hospital/place) |  |

**Network/Main cooperation partners**

The Centre's cooperation partners are registered in a master data sheet with the certification agency OnkoZert. The details in the master data sheet are published on [www.oncomap.de](http://www.oncomap.de/). Any new or no longer valid cooperation is to be notified immediately to OnkoZert, outside the certification period, too. Other updates (e.g. changes to the head, contact data) must be corrected in the master data sheet prior to the annual surveillance audit. The master data sheet with the registered cooperation partners can be requested from OnkoZert as a file.

**Table of Contents**

1 General Details of the Centre

 1.1 Structure of the network

1.2 Interdisciplinary cooperation

* 1. Cooperation with referring physicians and provider of aftercare treatment

1.4 Psycho-oncology

* 1. Social work and rehabilitation
	2. Patient involvement
	3. Study management
	4. Nursing care
	5. General service areas (pharmacy, nutritional counselling, speech therapy,...)
1. Organ-specific Diagnostics
	1. Consulting hours
	2. Diagnostics
2. Radiology
3. Nuclear Medicine
4. Surgical Oncology

5.1 Cross-organ surgical therapy

* 1. Organ-specific surgical therapy
1. Medicinal Oncology/ Systemic therapy
	1. Medical oncology
	2. Organ-specific systemic therapy
2. Radio-oncology
3. (Neuro-)Pathology
4. Palliative Care and Hospice Care
5. Tumour Documentation/Outcome Quality

Annexes to the Catalogue of Requirements

Data Sheet (Excel-Template)

**1. General information on the Breast Cancer Centre**

| **1.1 Structure of the network** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.1.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.1.2 | Cooperation agreementsMain cooperation partnersNeurosurgery, neurology, neuroradiology, neuropathology, radio-oncology, haematology and oncology and medicinal oncology Cooperation partnersIn addition to the cooperation partners mentioned in the Catalogue of Requirements, cooperation agreements are to be entered into with:pathology, neuropsychology, psychiatry, paediatric haematology and oncology, occupational therapy, ophthalmology, endocrinology and speech therapy. For further information, see FAQ. |  |
| 1.1.3 | Neurology and neurosurgeryNeurology and neurosurgery units with wards with 24-h on-duty presence, are a mandatory component in Neuro-Oncology Centres. |  |
| 1.1.4 | Cooperation with certified Centres for haematological neoplasias* For the treatment of CNS lymphomas, cooperations with Centres for haematological neoplasias may exist.
* In a cooperation agreement or SOP it has to be defined which treatment stages are provided by which cooperation partner.
* Counting patients with CNS lymphomas is possible for both partners under these conditions.
* The cooperating Centres are to be designated by name.
 |  |
| 1.1.5 | Cooperation with other certified Centres (entities from the network of the Oncology Centre)The cooperation for the care of patients with cerebral metastatis must be regulated in writing (SOP/ cooperation agreement). The following points must be regulated:1. Case-related involvement of the neurosurgeon in the organ-specific tumour board for patients with cerebral metastatis (telemedicine if necessary)

or* Presentation of patients with cerebral metastatis in the tumour board of the Neurooncology Centre

or* Consultative neurosurgical presentation of patients with cerebral metastatis ~~according to tumour board decision~~

2. For patients with cerebral metastases who present primarily to the NOC, organ-specific centres must be involved. The implementation must be proven with concrete patient examples  |  |

| **1.2 Interdisciplinary cooperation** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.2.1 | Number of primary casesThe Centre must treat 100 patients annually with a primary diagnosis of a neuro-oncological tumour. Definition:* Patients and not stays and not operations; in line with the list of primary cases at the end of the Catalogue of Requirements.
* Histology report must be available (biopsy or resection). Justified exceptions are to be listed (e.g. acoustic neurinoma, meningeoma, etc.).
* Patient with initial disease.
* The time of counting is the time of the histological confirmation of diagnosis or the time of clinical diagnosis by way of tumour board decision in the case of non-histologically confirmed tumours (e.g. acoustic neurinoma, meningeoma, etc.).

 Patients, who are only presented for the purposes of seeking a second opinion or for the purposes of consultation, are not included.(see also 5.2.3 Surgical primary cases) |  |
| 1.2.2 | Interdisciplinary pre-intervention tumour board CycleA tumour board must be staged at least once a week. Participants:Neurosurgeon, neurologist, neuroradiologist, neuropathologist, radiotherapist, internal oncologist\*.Related to the indication, e.g. in the case of cerebral metastases the presenting specialties are to be invited to the tumour board. \*Haematologist/oncologistIf the haematologist/oncologist is unable to attend the tumour board, he/she may be represented by the ~~neuro-oncologist~~ medical specialist responsible for chemotherapy (qualification in line with section 6.2 OC). For further information, see FAQ. |  |
| 1.2.3 | Interdisciplinary tumour boardAll primary case patients should be presented in the interdisciplinary tumour board: Elective patients: pre-intervention, emergency patients: at least post-intervention (Patient can only be taken into account 1x for the numerator). Scale of the discussed primary cases ≥95% For further information, see FAQ. |  |
| 1.2.4.a | Further presentation tumour board(not to be taken into account for the Data Sheet):* after completion of the neuropathological diagnosis when there was a corresponding recommendation of the tumour board pre-intervention;
* after completion of a therapy sequence;
* for each change in the clinical/imaging results a renewed presentation should be made in the interdisciplinary tumour board;
* emergency patients who were not discussed pre-intervention.
* All patients with recurrences, who have entrusted the Centre with their care, are to be presented.
* The general requirements for the tumour board as set out in section 1.2 CR OC must be met. In particular, suitable study patients must be considered in advance.

 Details of the number of presentations: |  |
| 1.2.4.b | For patients with advanced cancer who* have completed the guideline-based therapy and
* who, according to the clinical parameters, are able to receive a molecular-based therapy and
* who, in principle, agree to possible therapy based on the molecular findings,

a presentation at a Centre for Personalised Medicine should be sought.A prerequisite is the existence of a tumour board decision from an organ-specific centre. The MTB recommendation is provided to the referring centre. |  |
| 1.2.5 | GuidelinesIn addition to the requirement mentioned in Section 1.2.11 of the CR OC the following applies: * The main cooperation partners of the Centre must lay down uniform standards for diagnostics, therapy and aftercare (for instance in a quality circle) for neuro-oncological tumours for which there are no evidence-based guidelines.
* The standards must be updated and made known by the person responsible for the guidelines (see ER OC 1.2.12). Implementation must be checked by means of suitable measures. The process is to be described.
 |  |
| 1.2.6 | Morbidity /mortality conferences (M&M conferences)* The invited participants are the participants in the tumour board and referrers.
* The dates of these conferences can be timed to coordinate with the tumour board or with events for referrers.
* Both cases with a negative and a positive course are to be presented. M&M conferences are to be held 2x a year.
* M&S conferences are to be minuted.
 |  |

| **1.3 Cooperation with referring physicians and providers of aftercare treatment** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.3.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.3.2 | Referrer satisfaction survey* Every three years a referrer satisfaction survey must be conducted. The results of this survey are to be evaluated and analysed.
* The referrer satisfaction survey must be available for the first time for the first surveillance audit (1 year after initial certification).
 |  |

| **1.4 Psycho-oncology** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.4.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.4.2 | Documentation and EvaluationIn order to identify the need for treatment, screening of the level of mental stress is mandatory (Indicator "Psycho-oncological distress screening) and document the results. The proportion of patients subjected to distress over-threshold screening should be reported. Psycho-oncological counsellingPsycho-oncological care, in particular for patients with excessive stress in the distress screening, must be presented. For further information, see FAQ. |  |
| 1.4.3 | Psycho-oncology resourcesNeeds-based a least 1 psycho-oncologist with the above qualifications is available to the Centre (name is to be given). The personnel resources can be kept centrally, the organisation plan must be available. |  |
| 1.4.4 | Neuropsychology* 1 psychologist with the additional designation Clinical Neuropsychologist (GNP) is available to the Centre (if necessary via cooperation).
* Cooperation must be presented by way of documented cases during the assessment period.
* The following processes are to be described with details of responsibilities:
	+ patient presentation criteria;
	+ communication within the Centre;
	+ participation in events, quality circles, tumour boardand similar events of the Centre.

 For further information, see FAQ. |  |
| 1.4.5 | Additional content of the counselling:* Providing of information on outpatient psycho-oncological care after hospitalisation
 |  |

| **1.5 Social work and rehabilitation** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.5.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.5.2 | - section not assigned - |  |

| **1.6 Patient participation** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.6.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.6.2 | Patient surveys:* All patients should be given the opportunity to take part in a patient survey over a period of least three months every three years.
* The return rate should be more than 30% (to be evaluated if this rate is not reached)
 |  |
| 1.6.3 | Patient information should be made available as needed and preferably in written form. |  |
| 1.6.4 | Discharge interviewA conversation is held with each patient upon discharge (short documentation/checklist), in which at least the following topics are addressed and appropriate information is provided:* Therapy planning and diagnostic check-ups
* Individual aftercare plan (handover of aftercare pass)
* If applicable, "patient guideline" <www.leitlinienprogramm-onkologie.de>, flyer on self-help
 |  |
| 1.6.5 | If patient events are (co-)financed by industry, this fact, including potential conflicts of interest of the speakers, must be revealed. The Centre must exclude any direct influence on patients by industry stakeholders. For further information, see FAQ. |  |

| **1.7 Study management** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.7.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.7.2 | - Section not completed - |  |
| 1.7.3 | Study leaderThe name of the physician in charge of the study is to be given. Study assistance* The name of a study assistant is to be included in the "study organisation chart" for "each active study unit".
* He/she can work in a parallel manner for several "units conducting studies".
 |  |
| 1.7.4 | Proportion study patients 1. Initial certification:At the time of initial certification ≥1 patient must have been included in studies.2. after 1 year:at least 5% of malignant primary case number (ICD C70-72, C75.1-3) Only the inclusion of patients in studies with an ethical vote counts as study participation (non-interventional/diagnostic studies and prevention studies are also recognised, sole biobank collections are excluded).All study patients can be taken into account when calculating the study rate (share study patients based on the Centre's primary case number).General preconditions for the definition of the study quota:* Patients can be counted 1x per study, time: Date of patient's informed consent.
* Patients in the palliative and adjuvant situation can be counted, no limitations regarding stage of disease.
* Patients who are taking part in several studies simultaneously can be counted several times.
* The study rate can also be achieved in cooperation with other active units.
* Study patients can be counted for 2 centres, provided that the sending centre itself conducts at least one study for patients of the Neuro-Oncology Centre. If this counting method is chosen (optional), the centre must show how many patients are included in studies at their own centre, sent to other centres/clinics to participate in studies and taken from other centres/clinics to participate in studies – see also Excel template Data Sheet.

 For further information, see FAQ. |  |

| **1.8 Nursing care** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.8.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.8.2 | Specialist oncology nurses* At least 1 active specialist oncological nurse must be involved in the Centre.
* The names of specialist oncology nurses are to be provided.
 |  |

| **1.9 General service areas (pharmacy** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 1.9.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 1.9.2 | Speech therapyAt least 1 speech therapist is available to the Centre (possibly in cooperation).Tasks speech therapy:* Provision of further outpatient treatment: speedy outpatient access to speech, language and swallowing therapies is to be guaranteed via cooperation agreements.
* Voice and swallowing training, speech, language and swallowing diagnostics and therapy.
* Accompaniment by food intake
 |  |
| 1.9.3 | Occupational therapyAt least 1 occupational therapist is available to the Centre (possibly in cooperation).Tasks occupational therapy:* Provision of further outpatient treatment:
* Timely outpatient access is to be ensured via cooperation agreements in collaboration with social services.
* Regaining and/or maintaining the ability to act and, by extension, the greatest possible self-autonomy and independence.
* Sensorimotor-perceptual training.
* Cognitive and neuropsychological training.
* Advice and provision of aids.
 |  |

**2. Organ-specific diagnostics**

| **2.1 Consultation hours** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 2.1.1 | Information / dialogue with the patient Adequate information must be provided about diagnosis and therapy planning and a dialogue is to be entered into. This includes inter alia:* Presentation of alternative treatment concepts
* Offer of and aid in obtaining second opinions
* Discharge consultations as a standard procedure

 A general description is to be given of the way in which information is provided and the dialogue organised. This is to be documented for each patient in medical reports and minutes/records. |  |
| 2.1.2 | Conduct of consulting hoursFor the conduct of the consulting hours a* specialist for neurology or
* specialist for neurosurgery

is responsible. |  |
| 2.1.3 | Consulting hours in neurology and neurosurgery must be staged at least once a week and they must cover the following topics:* Initial examination after external suspicion or confirmation of diagnosis
* Planning of next diagnostic steps
* Passing on to the interdisciplinary tumour board
* Planning of the next therapeutic steps (based on the decision of the tumour board)
* Post-surgical aftercare
* Tumour aftercare

 Consultative discussion neurosurgery or neurology on a working dayIf appropriate, the topics can be covered in special, separate consulting hours. |  |
| 2.1.4 | Waiting times during the consulting hoursRequirement: < 60 min (target value) How long are the waiting times for an appointmentRequirement: < 2 weeks The waiting times are to be recorded on a random basis and statistically evaluated (recommendation: evaluation period 4 weeks a year). |  |
| 2.1.5 | From the consulting hours the following services/methods are to be ensured:* Access to imaging
* Consultative discussion neurosurgery or neurology on a working day
* Neuropsychological diagnostics
* Neurophysiological diagnostics, e.g. EEC
* Fluid diagnostics
* Neurological examination
 |  |
| 2.1.6 | The following quality-determining processes are to be described with details of the responsibilities:• Agreed course of diagnostics• Preparation of patients for the tumour board• In-patient admissionSufficient resources must be available to conduct the processes. |  |

| **2.2 Diagnostics** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 2.2.1 | Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |

**3. Radiology**

|  |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 3.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 3.2 | Specialists* At least 1 specialist in radiology with a focus on neuroradiology.
* Cross-over provision of staff with the same qualification is to be documented in writing.
* The names of the specialist and cover staff are to be given.

 The cooperation partner of neuroradiology may not be more than max 60 km away. |  |
| 3.3 | Radiology RTAs:At least 2 qualified RTAs must be available and their names given. |  |
| 3.4 | Necessary examination methods at the location:* Perfusion MRI
* Digital subtraction angiography (DSA)
* Optional: MR spectroscopy
 |  |
| 3.5 | Necessary therapeutic techniques on site:* Interventional catheterisation procedures
 |  |
| 3.6 | Neuroradiological assessment should be undertaken in line with the RANO/ iRANO criteria. |  |

**4. Nuclear medicine**

|  |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 4.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 4.2 | Additional examination methods (where appropriate via cooperation):• Amino acid PET/ CT (facultative) |  |

**5. Surgical oncology**

| **5.1 Multiple organ surgical therapy** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 5.1.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |

| **5.2 Organ-specific surgical therapy** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 5.2.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 5.2.2 | Specialists * At least 2 neurosurgery specialists
* The names of the specialists are to be given.
 |  |
| 5.2.3.a | Surgical primary cases At least 60 primary cases (Definition see CR 1.2.1) are operated every year.All surgeries (primary cases and recurrences) are to be performed under the supervision of the named surgeon (as 1. or 2. surgeon or along the lines of documented supervision). Definition surgical therapyGerman procedure classification (OPS): 5-015.0; 5-015.1; 5-015.3; 5-015.4; 5-016.0; 5-016.2; 5-016.4; 5-016.6; 5-017.1, 5-035, 5-075 For further information, see FAQ. |  |
| 5.2.3.b | Biopsies:Recording biopsies for primary cases: German procedure classification (OPS): 1-510.; 1-511; 1-512.; 1-514; 1-515 For further information, see FAQ. |  |
| 5.2.4 | Qualification surgeons* Per surgeon evidence of at least 25 open neuro-oncological operations/year (as 1st or 2nd surgeon as part of training of new surgeons).
* The special qualification of surgeons is documented via curricula.

 OPS classification:5-015.0; 5-015.1; 5-015.3; 5-015.4; 5-016.0; 5-016.2; 5-016.4; 5-016.6; 5-017.1; 5-035; 5-075 For further information, see FAQ. |  |
| 5.2.5 | Approval of new surgeons* Specialist for neurosurgery
* In addition to the specialist title: Proof of at least 50 operations on supra- or infratentorial tumours, 20 surgeries on spinal tumours (including vertebral metastases) and 20 biopsies performed with the support of computer-aided, three dimensional planning systems (e.g. stereotaxy, neuronavigation systems) (submission of surgical reports, performance as 1st surgeon)
 |  |
| 5.2.6 | Stereotaxy* 1 specialist for neurosurgery with key knowledge on stereotaxy must be available (can be identical with 5.2.2).
* Cover staff arrangements must be in place.
* Qualifications for frame-based biopsy must be shown ~~documented~~ in curricula / surgical logbooks or cooperation's.
* Requirement: 10 frame-based/frameless biopsies /year.
 |  |
| 5.2.7 | Training of new surgeonsPer centre and per 50 primary cases the training of further surgeons must be guaranteed and proven. |  |
| 5.2.8 | Structures/methods that must be available* Minimal invasive, stereotactic surgical methods also using neuronavigation
* Microsurgery
* Intraoperative electrophysiological monitoring (evoked potential, EMG, cortical and subcortical stimulation)
* Methods for intraoperative tumour localisation (intra-OP MRI, ultrasound, fluorescence
* Early postoperative MRI controls within 72 hours
* Intraoperative frozen section diagnosis by neuropathologist
 |  |
| 5.2.9 | On call/reachability neurosurgery24-hour reachability and surgical emergency care outside normal working hours including weekends and public holidays |  |
| 5.2.10 | The following quality-determining processes are to be described with details of the responsibilities:* Surgical preliminary preparation of patients
* Standard of surgical strategies
* Surgical aftercare
 |  |
| 5.2.11 | Postoperative complicationsTo be collected (cf. Data Sheet):* Revision surgeries due to intra- or postoperative complications in own Centre
* Clinically symptomatic postoperative haemorrhage
* Postoperative wound infections
 |  |
| 5.2.12 | Postoperative surveillance * Beds must be available for postoperative surveillance in the intensive care ward or intermediate care station.
* The processes for postoperative care and transfer to the normal ward are to be described, including responsibilities.
 |  |

**6. Medicinal oncology/ Systemic therapy**

| **6.1 Medical oncology** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 6.1.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 6.1.2 | Doctors' qualificationsSpecialist for internal medicine with the focus designation haematology and oncology Requirements (optional)Entitlement to specialty training by the competent medical association in the focus haematology and oncology The name of one representative with the above-mentioned qualification is to be given. |  |

| **6.2 Organ-specific systemic therapy** |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 6.2.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 6.2.2 | Autologous stem cell transplantation The option of autologous stem cell transplantation must be available, where appropriate, in cooperation. |  |

**7. Radio-oncology**

|  |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 7.0 | The Technical and Medical Requirements to be met by radio-oncology are summed up in the "Catalogue of Requirements Radio-Oncology" in a cross-organ manner. Independently of the number of Organ Cancer Centres / Modules, which work with a radio-oncology unit, this "Catalogue of Requirements Radio-Oncology" is only to be processed once and also only updated once per audit year (goal: no multiple presentations or on-site inspections within one audit year). The "Catalogue of Requirements Radio-Oncology" therefore constitutes an annex to this Catalogue of Requirements. Download cross-organ "Catalogue of Requirements Radio-Oncology" on <www.ecc-cert.org> |  |

**8. Pathology**

|  |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 8.0 | Alternatively, the Technical and Medical Requirements to be met by Neuropathology can be presented in the "Catalogue of Requirements Pathology". This is especially recommended when the pathology unit is named as a cooperation partner (one-off, cross-organ presentation) for further certified Organ Cancer Centres. In this case the Catalogue of Requirements "Pathology" is an annex to the Catalogue of Requirements and, consequently, is to be submitted, too. Download cross-organ "Catalogue of Requirements Pathology" on <www.ecc-cert.org> |  |
| 8.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 8.2 | Specialists* At least 2 specialist neuropathologists are available to the Centre (possibly in cooperation).
* The names of the specialists are to be given.
 |  |
| 8.3 | ~~MTAs~~ Medical technologist for laboratory analysis (MTLs)A sufficient number of qualified ~~MTAs /~~ MTLs technical assistants must be available. |  |
| 8.4 | Case numbers Institute/Department of Neuropathology Every year at least 1,000 histological, including cytological and immunohistochemical, tests (case numbers, proof via journal no.) |  |
| 8.5 | Histological classification* In line with the criteria of the current WHO classification 2021 of tumours of the central nervous system
* The histological, cytological, histochemical and immunohistochemical methods required under the WHO criteria must be established.
 |  |
| 8.6 | Stereotactic brain biopsiesPossibility of processing and gaining experience in the microscopic assessment of stereotactic brain biopsies must be available. |  |
| 8.6.1 | Assessment frozen sections / specimens* All frozen sections / sections are to be diagnosed by specialist for neuropathology~~ists~~ (as a rule on site, possibly via cooperation; cooperations > 45km are to be justified).
* In exceptional cases the cutting of the frozen section may be undertaken by pathologists on site. In these cases, the telemedical microscopic assessment of the frozen sections must be done by the neuropathology specialist.

 For further information, see FAQ. |  |
| 8.7 | Cytopathological assessmentPossibility of processing and gaining experience in the microscopic assessment of liquor-cytological specimens must be available. |  |
| 8.8 | Molecular diagnosticsPossibility to determine relevant neuro-oncological markers in line with WHO classification ~~2016~~ 2021 ~~(e.g. MGMT promoter methylation, 1p/ 19q deletion, mutations in the IDH1 gene)~~ (possibly in cooperation) and to gain experience in the assessment of molecular pathological findings must be available.There is an opportunity to perform and evaluate DNA methylome, RNA/DNA panel NGS (possibly in cooperation). |  |
| 8.9 | Asservation of tissue samplesIn addition to the asservation of the paraffin blocks and sliced specimens, there must be a possibility of asservation of shock-frozen tissue samples at at least -80 oC. |  |
| 8.10 | Participation in clinical trials and translational research projects* Provision/dispatch of tissue samples for reference histological evaluation as part of clinical trials
* Asservation, provision and possibly dispatch of tissue samples for translational research projects as part of clinical trials.
 |  |

**9. Palliative care and hospice care**

|  |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 9.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |

**10. Tumour documentation / Outcome quality**

|  |
| --- |
| **Section** | **Requirements** | **Explanatory remarks by the Cancer Centre** |
| 10.1 | The requirements of the Catalogue of Requirements Oncology Centres are to be met. Any special features of neuro-oncological tumours are to be described here with details of responsibilities. |  |
| 10.2 | Tumour documentation system* Tumour documentation, which contains the patient data for a minimum period of 3 months, must be in place at the time of initial certification.
* The patients with neuro-oncological tumours must be recorded in one tumour documentation system.

 Name of the tumour documentation system in a cancer registry and/or Centre A data set in line with the Uniform Oncological Basic Data Set (Einheitlicher Onkologischer Basisdatensatz) and its modules of the Working Group of German Tumour Centres (Arbeitsgemeinschaft Deutscher Tumorzentren - ADT) and the Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland - GEKID) must be used. The Centre must ensure that the data transfer to the competent cancer registry is done in a timely manner. Any existing federal state laws for notification deadlines are to be complied with. For further information, see FAQ. |  |

**Data Sheet**

A Data Sheet (EXCEL template) is available for presenting the Basic Data, indicators and other data from the Centre. The Data Sheet is an appendix to the Catalouge of Requirement.

The EXCEL template can be downloaded from <http://ecc-cert.org/> and [www.onkozert.de](http://www.onkozert.de/)